Klinika Ambroziak Sp. z o.o. — Clinical Trial Site

68 Registered trials

20 Currently recruiting

Organisation

Klinika Ambroziak Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100045213

Address

Ul. Ulica Kosiarzy 9a, 02-953, Poland

Departments

-
#45002: Klinika Ambroziak Dermatologia
#4801: NA
#5701:Dermatology
2503 : Dermatology
502: Klinika Ambroziak Dermatologia
7404:Klinika Ambroziak Dermatologia
9228:Klinika Ambroziak Dermatologia
Ambroziak Dermatologia
Dermatologia
Dermatology
Dermatology Clinic
Klinika Ambroziak
Klinika Ambroziak Dermatologia
Klinika Ambroziak Dermatologi
Klinika Ambroziak Dermatologia
Klinika Ambroziak Sp. z o.o.
N/A
N/A. Private institution
NA
Warszawa

Clinical trials at this site (68)

Search interface

A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo… Recruiting

2025-520499-24-00 Moderate to Severe Platysma Prominence 5 2025-10-01
This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting

2023-504713-76-00 Dermatitis atopic 5 2024-12-03
A Phase 3 Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 Years of Age With Severe Alopecia Areata Ended

2024-515438-33-00 Alopecia areata 5 2026-01-12
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513266-19-00 Hidradenitis Suppurativa (HS) 5 2025-06-13
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis. Ended

2024-515672-12-00 Moderate to Severe Genital Psoriasis 5 2025-05-27
A Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis Ended

2024-515494-95-00 Moderate to Severe Atopic Dermatitis (AD) 4 2025-05-26
Hidradenitis Suppurativa: Evaluation of lutikizumab in Adult and Adolescent Subjects Ended

2024-510730-40-00 Hidradenitis Suppurativa 5 2024-12-12
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata Patients (Rezolve AA) Ended

2023-509981-39-00 Alopecia Areata 4 2024-11-20
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510339-12-00 acne vulgaris 5 2024-11-11
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended

2023-503692-24-00 Cutaneous Lupus Erythematosus 5 2024-09-25
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended

2023-507456-69-00 Atopic Dermatitis 4 2024-04-25
Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended

2023-506011-18-00 Vitiligo 5 2024-04-17
A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo. Ended

2023-506195-27-00 non-segmental vitiligo 5 2024-04-05
Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended

2023-504443-13-00 moderate to severe atopic dermatitis 5 2024-01-29
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS) Ended

2022-502700-78-00 Alopecia areata (AA) 5 2023-09-01
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 5 2021-01-11
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of… Ended

2024-517814-13-00 Moderate to Severe Atopic Dermatitis 4 2025-04-30
A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder… Ended

2024-511549-20-00 Dermatitis atopic 4 2025-04-22